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Abstract
Extensive research strongly suggests that amyloid beta (Aβ) aggregates in the brain have a
central role in Alzheimer’s disease (AD) pathogenesis. Pathological Aβ deposition is likely
due to an altered balance between overproduction and elimination. Rodent studies have
suggested that the liver has a major role in Aβ degradation. It is possible alterations of liver
function could affect brain Aβ levels through changes in blood Aβ concentration. In this
study, we hypothesized hepatic Aβ degradation to be impaired in AD subjects. To test our
hypothesis, an Aβ degradation assay was developed using synthetic fluorescein-labeled
Aβ40 and Aβ42 spiked into human liver homogenates. Aβ degradation rates were lower in
AD-derived homogenates as compared with those from non-demented (ND) control sub-
jects, even after accounting for such covariates as age, sex, and APOE genotype. The pro-
tein expression of potential Aβ-degrading enzymes were also examined. Neprilysin levels
were not different in AD liver samples, while cathepsin D and insulin-degrading enzyme
were significantly altered in AD subjects. The results support the possibility that impaired
hepatic Aβ degradation could be a factor contributing to increased brain Aβ accumulation
and AD.
Introduction
It is well accepted that aggregation of amyloid beta (Aβ) peptides into amyloid plaques is a crit-
ical step in the pathogenesis of Alzheimer disease (AD). Studies of early-onset forms of familial
AD, Down syndrome, and transgenic rodent models that overexpress normal or mutated
forms of the amyloid precursor protein (APP) suggest formation of amyloid plaques may play
a key role in the disease [1, 2]. However, it is important to emphasize that familial mutations in
humans account for less than 1% of AD cases, and while much of the investigative focus has
been on overproduction of Aβ, it is possible that disease initiation or acceleration could also be
due to decreased brain clearance or degradation. The major proposed mechanisms of cerebral
Aβ elimination are receptor-mediated transport across the blood-brain-barrier and proteolytic
degradation in the brain by enzymes such as insulin degrading enzyme (IDE), cathepsin D
and neprilysin [3–7]. Experimental animal studies have also indicated that circulating Aβ is
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metabolized by both liver and kidney [8, 9]. However, to our knowledge, there are no previous
studies exploring the ability of the human liver to degrade Aβ and whether this might differ in
subjects with and without AD. In this study we used human postmortem liver homogenates to
compare Aβ degradation rates in non-demented (ND) control subjects and subjects with AD.
Materials and methods
Human subjects
Liver samples came from subjects who were volunteers in the Arizona Study of Aging and
Neurodegenerative Disorders (AZSAND), a longitudinal clinicopathological study of normal
aging, cognition and movement in the elderly since 1996 in Sun City, Arizona [10]. Autopsies
are performed by the Banner Sun Health Research Institute Brain and Body Donation Pro-
gram (BBDP: www.brainandbodydonationprogram.org). All subjects signed Western Institu-
tional Review Board-approved informed consents allowing both clinical assessments during
life and several options for brain and/or bodily organ donation after death." The name of the
IRB is Western Institutional Review Board, Seattle Washington and its approval include the
collection of human organs at autopsy for unlimited number of research studies, including
this one. Most subjects are clinically characterized with annual standardized test batteries con-
sisting of general neurological, cognitive and movement disorders components, including the
Mini Mental State Examination (MMSE). Subjects for the current study have had a complete
pathological evaluation by a licensed pathologist (Table 1; N = 16) and were chosen by search-
ing the BBDP database for cases with a whole-body autopsy and a clinicopathological diagnosis
of AD (N = 8) or control (N = 8) and low post mortem interval. Exclusion criteria included
clinical history of liver disease, hepatitis, severe fibrosis and cirrhosis, as well as other comor-
bid brain pathology including Lewy body disease, vascular dementia and non-AD tauopathies.
Pathological examination
Complete pathological examination was performed using standard AZSAND methods [10, 11]
and consisted of gross and microscopic examination, including pathologist assessment of both
brain and peripheral organs. All areas were stained with hematoxylin and eosin for general
pathological assessment. Standard brain areas were also stained with thioflavin S, Gallyas, and
Campbell-Switzer methods to detect the presence of senile plaques, neurofibrillary changes
and other neuronal and glial tauopathies [10–14]. Immunohistochemical staining was used to
document the presence of alpha-synuclein pathology [15–17]. Neuritic plaque and neurofibril-
lary tangle (NFT) densities were graded blindly as recommended by CERAD with separate
semi-quantitative density estimates of none, sparse, moderate, or frequent [18]; all scores were
converted to a 0–3 scale for statistical purposes. Regions scored included cortical gray matter
from frontal (F), temporal (T), parietal (P), hippocampal CA1 (H), and entorhinal (E) regions.
Neurofibrillary degeneration was also staged on thick frozen sections by the original method
Table 1. Patient demographics.
Diagnosis Expired Age,
years (SD)
Gender PMI, hours (SD) Total Plaque Score (SD) Liver
Weight (SD)
NDC (n = 8) 83 (8.7) 8M:0F 2.9 (0.48) 4.25 (4.92) 1431.3g (457.7)
AD (n = 8) 83 (7.7) 5M:3F 3.0 (0.54) 14.38 (0.88) 1064.4g (305.9)
NDC, non-demented control; AD, Alzheimer’s disease; SD, standard deviation; M, male; F, female; PMI, postmortem interval
 = p<0.0001
https://doi.org/10.1371/journal.pone.0203659.t001
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of Braak [12], and clinicopathological AD diagnoses were made when subjects were demented
and met “intermediate” or “high” probabilities, according to National Institute on Aging/Rea-
gan Institute criteria [19–21].
Liver homogenization
Frozen liver (~500 mg) was ground into a powder in liquid nitrogen with a mortar and pestle
then transferred to 8 ml sucrose lysis buffer (SLB: 20 mM HEPES, 1.5 mM magnesium chlo-
ride, 10 mM potassium chloride, 40 mM sucrose, 1 mM EDTA, 2% glycerol, 0.5% sodium
deoxycholate, 1% Tergitol, pH 7.9) at 4˚C. The tissue was then homogenized using an Omni
TH tissue grinder (Kennesaw, GA) at 4˚C. The homogenates were centrifuged at 15,000 x g in
a Type 50.4 Ti rotor (Beckman Coulter, Brea, CA) for 20 min at 4˚C and the supernatant was
collected. Total protein was determined with Pierce’s Micro BCA protein assay kit (Thermo
Fisher Scientific, Waltham, MA).
Degradation of fluorescein-labeled Aβ
Lyophilized fluorescein-labeled Aβ40 and Aβ42 peptides (FAβ, rPeptide, Bogart, GA) were
reconstituted in DMSO to 1 mg/ml and stored at 4˚C [22]. For degradation experiments, the
stock peptides were diluted to 0.4 μg/ml (1:2500) in sucrose lysis buffer (SLB), 5 μl of either
FAβ40 or FAβ42 was added to the reaction mixtures and samples were incubated at 37˚C for 1
h or 2 h (for ELISA and Western experiments). In addition, two 0 h incubations were included:
one liver homogenate with 5 μl of FAβ as well as a negative control sample without FAβ. Reac-
tions were terminated by placing homogenates on ice and by adding SLB with complete prote-
ase inhibitor cocktail (PIC, Roche, Mannheim, Germany). Reactions used for Western blots
were stopped by 2XLDS sample buffer (Invitrogen) containing 100 mM dithiothreitol.
Analysis by ELISA and immunoblot
All 4 sample sets were analyzed in triplicate with Aβ40 and Aβ42 ELISAs (Invitrogen; catalog #
KHB3481 and KHB3441 following the manufacturer’s instructions. Similar sets of samples
were analyzed for FAβ by Western blot (as described below) with an anti-fluorescein antibody
(Table 2) which binds to both to both free and bound fluorescein.
Liver homogenates were assessed for Aβ-degrading enzymes as follows: Eight μg of total
protein was brought up to 20 μl with NuPage 2XLDS sample buffer (Invitrogen, Carlsbad, CA)
containing 100 mM dithiothreitol then heated at 80˚C for 10 min. The liver proteins were sep-
arated on 4–12% Bis-Tris gels (Invitrogen; catalog # NP0336BOX) using NuPage 1XMES run
buffer and NuPage antioxidant (Invitrogen). The Precison Plus Protein Dual Xtra Prestained
Protein Standard from Bio-Rad (Hercules, CA; catalog # 161–0377) was used to determine
Table 2. Antibodies used in western blots.
Primary antibody Antigen specificity or immunogen Secondary antibody Company/Catalog #
Anti-fluorescein KLH-bound fluorescein M Sigma Aldrich/11426320001
Neprilysin (anti-CD10) Synthetic peptide corresponding to Human CD10 aa 50–500 R Abcam/ab126593
Cathepsin D Human cathepsin D M BD Transduction Labs/610800
IDE purified human erythrocyte IDE M Covance/mms-282R
GAPDH Full-length human GAPDH protein M Life Technologies/39-8600
aa, amino acid; CTF, C-terminal fragment; IDE, insulin degrading enzyme; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; M, HRP conjugated AffiniPure goat-
anti mouse IgG (catalog # 115-035-146, Jackson Laboratory); R, HRP conjugated AffiniPure goat-anti rabbit IgG, (catalog # 111-035-144, Jackson Laboratory).
https://doi.org/10.1371/journal.pone.0203659.t002
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molecular weight. NuPage transfer buffer with 20% methanol was used to transfer proteins
onto 0.45 μm pore nitrocellulose membranes. The membranes were blocked with 5% Quick-
Blocker (G-Biosciences, St. Louis, MO) in phosphate buffered saline (PBS), 0.5% Tween 20
(PBS-T), then incubated overnight at 4˚C in primary diluted in blocking buffer (see Table 2
for list of antibodies). The membranes were washed 4X in PBS-T for 5 min each and the blots
were then incubated in secondary antibody (Table 2) that was also diluted in blocking buffer
for 1 h at room temperature. SuperSignal WestPico Chemiluminescent substrate (Thermo
Fisher Scientific), CL-Xposure film and a Konica Minolta SRX-101A film processor (Wayne,
NJ) were used to detect protein bands. A GS-800 calibrated densitometer (Bio-Rad) scanned
the films and Quantity One software (Bio-Rad) was used for densitometry analysis.
Statistical methods
For comparing group measures, the Mann-Whitney U-Test, were used to analyze group differ-
ences, linear and Spearman regressions were used to correlate % Aβ degradation with post-
mortem interval (PMI), number of liver pathologies, age at death and liver weight. Multiple
linear regression was applied to study possible correlation between the observed benign liver
pathology and hepatic Aβ degradation.
Results
Both groups had similar ages at death and PMI (Table 1). Half of the cases in each group were
heterozygous for the APOE allele 4, while the other half were non-carriers. Some cases had
miscellaneous benign hepatic pathology such as liver atrophy, passive liver congestion and
mild steatohepatitis, but the proportion of these were not different between the ND and AD
group (S1 Table). There was a trend for liver weight loss in AD subjects, but this difference was
not statistically significantly different. Multiple linear regressions and Spearman correlations
were used to analyze possible correlations of hepatic Aβ degradation with benign liver patholo-
gies, age, PMI and liver weight, but no significance was found with any of the variables
analyzed.
As expected, the CERAD neuritic plaque density and Braak stage showed significant differ-
ences when the ND controls were compared to the AD group (Table 1; p<0.0001). Western
blot (Fig 1) and ELISA (Fig 2) results showed faster Aβ degradation in the liver of ND subjects
as compared to the AD group. Thirty-four percent of Aβ40 was degraded within an hour in
the ND group compared to 23% in the AD samples (p<0.05) (Fig 2). Surprisingly, Aβ42
degraded faster than Aβ40. Within 2 hours, 94% of Aβ42 was degraded by the ND homoge-
nates while this was 80% for the AD group (p = 0.07) (Fig 2). Basal concentrations Aβ40 or
Aβ42 were not detectable without the presence of the monomeric fluorescein-labeled Aβ40 or
Aβ42 peptides. The presence of the APOE 4 allele did not show an effect on Aβ degradation
rate. Western blots showed that AD liver homogenates had lower expression of IDE (p<0.001)
and higher levels of cathepsin D (Fig 3; p<0.05) while there was no significant difference in
neprilysin levels.
Discussion
It is well known that neurotoxic Aβ peptides form into insoluble filaments that accumulate
into cerebral amyloid plaques and around blood vessel [23, 24]. There is also recognition that
amyloid deposition may be triggered by either overproduction or decreased brain elimination
of Aβ [7]. It is possible both scenarios may be occurring in the aged brain, along with many
other factors that disrupt brain homeostasis and precipitate neurodegeneration. While many
studies have focused on Aβ production and clearance within the brain, to our knowledge,
Hepatic amyloid-beta degradation in Alzheimer’s disease
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there have been no prior investigations of the role of the liver in Aβ metabolism in human sub-
jects. In this study we investigated whether the metabolism of Aβ in the liver is affected in AD
using fluorescein-labeled Aβ40 and Aβ42 peptides. The rapid metabolism rates of these pep-
tides in the liver make it almost impossible to relay on endogenous levels of Aβ detected after
death, even at short PMI. Therefore, we took advantage of methodologies previously published
by M.A. Leissring, et al in 2003 [22], where they demonstrated that monomeric fluorescein-
labeled Aβ40 and Aβ42 peptides were very stable and behaved similarly to wildtype Aβ, and
investigated the metabolic capabilities of liver homogenates using these peptides. Ghiso et al.
2004 showed in animals that peripheral organs such as the liver, kidney, stomach and spleen
are also involved in Aβ clearance. Their results suggest that liver is the main organ that metab-
olized more than 60% of Aβ [8]. Our results validate the involvement of the liver degrading Aβ
in humans and are also indicative of possible Aβ metabolism deficiencies in the liver of AD
subjects. The mechanism of such deficiency is unclear, however the expression of two proteo-
lytic enzymes were altered in AD liver as previously observed in AD brain [25, 26]. The con-
centration of cathepsin D was increased in the AD group while that of insulin degrading
enzyme was decreased. Aβ can be cleared through the autophagy-lysosomal system and it is
been well reported that deficit in the lysosomal degradation function leads to accumulation of
Fig 1. Representative western blot showing faster Aβ degradation in the liver of non-demented controls subjects
when compared to the AD group. Lyophilized fluorescein-labeled Aβ40 (A) or Aβ42 (B) peptides were added to liver
homogenates to quantify its degradation. Sucrose lysis buffer containing complete protease inhibitor cocktail was
added to stop the reaction and Western blot performed to visualized Aβ degradation (molecular weight ~7kDA).
https://doi.org/10.1371/journal.pone.0203659.g001
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Aβ aggregates [26, 27]. Lysosomal proteases, such as cathepsin D plays a major role in AD
through clearance of accumulated Aβ aggregates and previous studies have reported elevated
expression in neurons of AD subjects. This apparent discrepancy is not yet clear and to our
Fig 2. ELISA measurements of Aβ40 and Aβ42 degradation in liver homogenates from non-demented controls
(NDC) and Alzheimer’s disease (AD) subjects. Homogenates from NDC degraded Aβ faster than AD subjects. Aβ40
degraded slower (A) than Aβ42 (B) and even though both peptides degraded faster in the NDC group.
https://doi.org/10.1371/journal.pone.0203659.g002
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knowledge have not been well studied. What is well established is that any dysregulation in the
protease expressions and/or their proteolytic activities disrupts cellular homeostasis. We spec-
ulate that elevation of protein expression could be a compensatory mechanism due to
decreased proteolytic activity.
Decreased liver Aβ metabolism might result in brain Aβ accumulation, because one can
hypothesize this could result in elevated blood Aβ levels throughout an individual’s life and
could result in increased entry of Aβ into the brain. Over decades, disruption of homeostatic
Aβ entry and clearance could eventually result in brain plaque formation, analogous to the
early onset of Aβ brain deposits in Down’s syndrome due to whole-body overexpression of
APP [28, 29]. Many have postulated once plaques form in the brain, they could then act as a
“sink”, drawing down blood Aβ concentrations [30, 31]. However, removing Aβ from the
periphery with solanezumab does not seem to remove PET-detectable Aβ from the brain,
therefore it might seem that modification of peripheral metabolism might be irrelevant to AD.
The failure of solanezumab to remove Aβ deposits from the brain could be due to many fac-
tors, but perhaps most plausibly because once Aβ is sequestered in insoluble plaques, a simple
concentration gradient may not be sufficient to dissolve the deposits. We acknowledge, how-
ever, that our findings showing lower levels of hepatic Aβ degradation rates in AD could be a
result of the disease, rather than a contributing factor to disease and it is possible liver homoge-
nates in vitro may not faithfully mimic liver metabolism in vivo, but these results are intriguing
and support further study of the role of the liver in AD pathogenesis.
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